CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes.
Antineoplastic Agents
/ pharmacology
Biomarkers, Tumor
CD8-Positive T-Lymphocytes
Computational Biology
/ methods
DNA Methylation
Databases, Genetic
Disease Susceptibility
Epigenesis, Genetic
Extracellular Matrix Proteins
/ genetics
Gene Expression
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Neoplasm Staging
Neoplasms
/ diagnosis
Organ Specificity
Prognosis
Promoter Regions, Genetic
Protein Interaction Mapping
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 10 2021
06 10 2021
Historique:
received:
17
06
2021
accepted:
14
09
2021
entrez:
7
10
2021
pubmed:
8
10
2021
medline:
29
12
2021
Statut:
epublish
Résumé
According to the previous reports, the collagen triple helix repeat containing 1 (CTHRC1) causes tumorigenesis by modulating the tumor microenvironment, however, the evidence is limited to a few human cancer subtypes. In the current study, we analyzed and validated the CTHRC1 expression variations in 24 different human cancer tissues paired with normal tissues using publically available databases. We observed that CTHRC1 was overexpressed in all the 24 major subtypes of human cancers and its overexpression was significantly associated with the reduced overall survival (OS) duration of head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), liver hepatocellular carcinoma (LIHC), Lung adenocarcinoma (LUAD), stomach adenocarcinoma (STAD), and Uterine corpus endometrial carcinoma (UCEC). This implies that CTHRC1 plays a significant role in the development and progression of these cancers. We further noticed that CTHRC1 was also overexpressed in HNSC, KIRC, LIHC, LUAD, STAD, and UCEC patients of different clinicopathological features. Pathways enrichment analysis revealed the involvement of CTHRC1 associated genes in seven diverse pathways. We also explored few interesting correlations between CTHRC1 expression and promoter methylation, genetic alterations, CNVs, CD8+ T immune cells infiltration, and tumor purity. In conclusion, CTHRC1 can serve as a shared diagnostic and prognostic biomarker in HNSC, KIRC, LIHC, LUAD, STAD, and UCEC patients of different clinicopathological features.
Identifiants
pubmed: 34615943
doi: 10.1038/s41598-021-99321-w
pii: 10.1038/s41598-021-99321-w
pmc: PMC8494806
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
CTHRC1 protein, human
0
Extracellular Matrix Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19873Informations de copyright
© 2021. The Author(s).
Références
Front Genet. 2020 May 26;11:420
pubmed: 32528519
Cancer Res. 2002 Dec 15;62(24):7350-6
pubmed: 12499279
Environ Health Perspect. 2003 May;111(6):793-5
pubmed: 12760826
ScientificWorldJournal. 2012;2012:761909
pubmed: 22606061
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Neuropsychopharmacology. 2013 Jan;38(1):23-38
pubmed: 22781841
Mol Genet Genomic Med. 2019 May;7(5):e607
pubmed: 30793530
Science. 2003 Aug 8;301(5634):798-802
pubmed: 12907790
Cancer Cell Int. 2019 Nov 29;19:318
pubmed: 31798347
Cell Rep. 2018 Oct 30;25(5):1318-1331.e4
pubmed: 30380421
Oral Oncol. 2017 Apr;67:70-76
pubmed: 28351583
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Oral Oncol. 2018 Jun;81:52-60
pubmed: 29884414
CA Cancer J Clin. 2011 Jul-Aug;61(4):212-36
pubmed: 21685461
Cell Rep. 2021 Jan 5;34(1):108597
pubmed: 33406434
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Front Pharmacol. 2020 Jun 10;11:875
pubmed: 32587519
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Cancer Med. 2018 Nov;7(11):5643-5654
pubmed: 30302922
Nucleic Acids Res. 2003 Jan 1;31(1):258-61
pubmed: 12519996
Am J Surg Pathol. 2013 Oct;37(10):1469-89
pubmed: 24025519
FEBS Open Bio. 2018 May 30;8(7):1093-1103
pubmed: 29988590
BMC Genet. 2020 Sep 22;21(1):113
pubmed: 32962636
Mol Cancer. 2015 May 20;14:107
pubmed: 25990935
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Immunol Res. 2016;2016:4273943
pubmed: 28116316
J Clin Oncol. 2006 Sep 1;24(25):4170-6
pubmed: 16943533
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Int J Clin Exp Pathol. 2018 Feb 01;11(2):847-854
pubmed: 31938174
Med Sci Monit. 2020 Jun 24;26:e922070
pubmed: 32578582
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Oncotarget. 2014 Oct 15;5(19):9410-24
pubmed: 25238260
Biochem Biophys Res Commun. 2020 Apr 30;525(2):418-424
pubmed: 32102754
Future Oncol. 2019 Sep;15(27):3103-3110
pubmed: 31368353
Front Oncol. 2020 Feb 05;10:68
pubmed: 32117725
BMC Med Genomics. 2019 Jul 11;12(Suppl 5):101
pubmed: 31296229
PLoS One. 2021 Apr 16;16(4):e0249881
pubmed: 33861762
Yale J Biol Med. 2006 Dec;79(3-4):85-94
pubmed: 17940618
Clin Oral Investig. 2019 Aug;23(8):3319-3329
pubmed: 30498981
Genome Biol. 2007;8(9):R183
pubmed: 17784955
J Histochem Cytochem. 2013 May;61(5):330-9
pubmed: 23392733
Am J Cancer Res. 2016 Aug 01;6(8):1820-7
pubmed: 27648368
Clin Exp Metastasis. 2019 Aug;36(4):351-363
pubmed: 31119444
BMC Cancer. 2018 Apr 10;18(1):400
pubmed: 29631554